BeOne Medicines presented 78-month data for Brukinsa showing sustained disease control in patients with chronic lymphocytic leukemia at the 2026 American Society of Clinical Oncology Annual Meeting [1].

These results are significant because they establish a new benchmark for long-term disease control in CLL. The data supports the possibility of time-limited treatment approaches, which could reduce the duration of therapy for patients while maintaining efficacy [1], [3].

According to the data presented at ASCO 2026, the drug, known generically as zanubrutinib, demonstrated a 74% progression-free survival rate over six years for treatment-naïve patients [2]. The total duration of follow-up reported for the therapy reached 78 months [1].

BeOne Medicines, a global oncology company, is positioning Brukinsa as a standard for long-term management of the disease [1], [3]. The company has seen significant financial growth tied to the drug's performance. In 2025, Brukinsa generated $3.93 billion in revenue [4].

This financial performance represents a 49% year-over-year growth for the drug during 2025 [4]. The company said these clinical findings should influence how physicians approach the treatment of CLL over extended periods [1], [3].

“Brukinsa demonstrated a 74% progression-free survival rate over six years”

The 78-month data suggests that Brukinsa can maintain efficacy over a period long enough to potentially shift the treatment paradigm from indefinite administration to time-limited therapy. If successful, this would reduce the cumulative toxicity and cost of care for CLL patients without compromising survival outcomes.